Trial Profile
A Phase II Study of Gemcitabine and Pazopanib in Metastatic Pancreatic Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 18 Jun 2015
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Pazopanib (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 05 Feb 2013 Actual initiation date changed from Jun 2010 to Aug 2010 as reported by ClinicalTrials.gov.
- 05 Feb 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
- 03 Jun 2010 Actual initiation date (1 Jun 2010) added as reported by ClinicalTrials.gov.